CONSTELLATIONS Living Lab: Improving the Care Transitions of Older Adults Living with Neurocognitive Disorders
Launched by LAVAL UNIVERSITY · Sep 19, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The CONSTELLATIONS Living Lab is a clinical trial aimed at improving the way older adults with neurocognitive disorders, like Alzheimer’s disease and dementia, transition between different types of healthcare. Many patients and their caregivers face challenges when moving from one healthcare setting to another, which can lead to confusion and poor care. To tackle this issue, the trial will implement a program called CoMPAS+ MNCD that focuses on better communication and coordination among healthcare providers. Over two years, the research team will work with local healthcare organizations to identify challenges and develop solutions to make these transitions smoother.
To participate in the trial, you need to be 65 years or older and either have a major neurocognitive disorder or be a caregiver for someone who does. You must live in the Chaudière-Appalaches region and be able to give consent for your medical information to be used in the study. If you join, you can expect to help improve the care process for others in similar situations by sharing your experiences and opinions. This trial is important because it aims to create a more patient-centered healthcare system that better supports older adults and their caregivers during difficult transitions.
Gender
ALL
Eligibility criteria
- • Study population for the evaluation of the impact of the CoMPAS+ MNCD Program on the care transitions of patients living with MNCD and their caregivers (Micro level)
- Inclusion criteria:
- • Be 65 years of age or older;
- • Be living with a major neurocognitive disorder in the process of clinical evaluation or already diagnosed;
- • Reside in the socio-sanitary region of the CISSS CA;
- • Be able to consent independently to research (for users without caregivers at the beginning of their illness);
- • Reside at home or in a retirement home or in an intermediate residence or a family-type resources;
- • Consent to the research team collecting data in their medical records (FMG Electronic Medical Record (EMR) when accessible, Hospital Electronic Patient Record (EPR) when accessible, etc.).
- • OR
- • Be the caregiver of a person 65 years of age and older living with a major neurocognitive disorder in the process of clinical evaluation or already diagnosed;
- • The person being cared for must reside in the socio-sanitary region of the CISSS CA;
- • Consent to the research team collecting data from the medical records of the person being cared for (FMG Electronic Medical Record (EMR) when accessible, Hospital Electronic Patient Record (EPR) when accessible, etc.);
- • Be able to consent independently to research.
- Exclusion criteria:
- • Users living with major neurocognitive disorder under 65 years of age;
- • User living in a provincial long-term care facility at the time of recruitment;
- • User 65 years of age and older living with a major neurocognitive disorder, unable to consent independently to research, without a caregiver, or without a caregiver able to consent independently to research;
- • Users aged 65 and over living with a major neurocognitive disorder, residing in a territory other than that of the CISSS CA;
- • User refusing to consent to the collection of data in their medical records; OR
- • Caregiver of a user living with a major neurocognitive disorder who does not reside in the CISSS CA territory or who is not 65 years of age or does not live at home, in a retirement home or in an IR or who died before the start of the study (T=0).
- • Caregiver refusing to consent to the collection of data in the medical records of the person being cared for.
- • Study population for the assessment of the intention to apply best practices of CoMPAS+ MNCD workshop participants (Meso level)
- Inclusion criteria:
- ● Be a participant in the CoMPAS+ MNCD workshops and be part of at least one of the following categories of participants:
- • Health professionals working in a CISSS CA health facility or with a community organization;
- • CISSS CA decision-makers or local managers;
- • Community service representative (e.g., Alzheimer's Society, L'APPUI);
- Exclusion criteria:
- • Research team members
- • Workshop facilitators
- • INESSS professionals
- • Users and partner caregivers
- • Person unable to consent
- • Person refusing to consent
- • Study population for the evaluation of the potential to scale-up and sustainability of the CoMPAS+ MNCD Program within the CISSS CA (Meso level)
- • Inclusion criteria
- ● Be part of one of the following categories of actors and be involved in the implementation of the CoMPAS+ MNCD Program:
- • Health professionals working at the CISSS CA or in the community participating in the CoMPAS+ MNCD workshops;
- • CISSS CA decision-makers;
- • Users and partner caregivers;
- • Community service representatives (e.g., Alzheimer's Society, L'APPUI);
- • Members of the research team (except the person in charge of this component (Laetitia Bert), Alexander Cornea (research assistant), Martyne Audet (scientific coordinator), Clémence Dallaire, André Côté, Félix Pageau, Catherine Paquet);
- • Research coordinator responsible for the involvement of partner users in the conduct of the workshops (Émilie Côté);
- • INESSS professionals;
- • Workshop facilitators
- • Representative of the Ministry of Health and Social Services (MSSS).
- • Exclusion criteria
- • Person unable to consent;
- • A person refusing to consent;
- • Member of the research team responsible for carrying out this part of the study or by the scientific coordination of this project (Laetitia Bert, Alexander Cornea, Martyne Audet (scientific coordinator), Clémence Dallaire, André Côté, Félix Pageau, Catherine Paquet).
About Laval University
Laval University is a prestigious research institution located in Quebec, Canada, renowned for its commitment to advancing knowledge and innovation in various fields, including health sciences. The university actively engages in clinical trials aimed at exploring new therapeutic interventions and improving patient outcomes. With a strong emphasis on ethical standards and rigorous scientific methodologies, Laval University collaborates with multidisciplinary teams of researchers, healthcare professionals, and industry partners to conduct high-quality clinical research. Its state-of-the-art facilities and dedication to fostering a culture of inquiry position Laval University as a leader in clinical research, contributing significantly to the understanding and treatment of diverse medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Québec, Quebec, Canada
Patients applied
Trial Officials
Patrick M Archambault, MD, MSc, FRCPC
Principal Investigator
Laval University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported